Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Individualized drug therapy with azacitidine (75 mg/m 2 per dose daily by subcutaneous injection for 7 consecutive days in 28-day cycles) and trametinib (0.035 mg/kg per dose daily per os) as previously described [10] was initiated on day of life 47 and followed by rapid reduction of the extensive leptomeningeal thickening (Fig
10.1016/j.ejphar.2014.01.046 31 DuzelA.VlainicJ.AntunovicM.MalekinusicD.VrdoljakB.SamaraM.et al (2017)
If already shipped, refund = item price minus shipping & return fees
10.4161/auto.29456[Epub ahead of print]
PSGs are critical in: Facilitating generic drug development Streamlining ANDA assessments Supporting timely access to affordable treatments Aligned with the FDA's Drug Competition Action Plan and Executive Order 14273, these PSGs aim to lower drug costs and enhance access to critical therapies
US$ 21.32
US$ 27.25
US$ 24.85
US$ 27.42
US$ 20.34
